What is the impact of delays in postoperative head and neck (HN) chemoradiotherapy on overall survival?
An overall treatment time (OTT) of greater than approximately 14 weeks most consistently increased the risk of death. Assuming they can complete a six-week treatment regimen without breaks, patients should start chemoradiotherapy within eight weeks of surgery.
Explore this issue:October 2018
Background: Delays in adjuvant HN treatment can result in decreased disease control and survival. Two large clinical trials established the role of combined adjuvant radiation therapy with chemotherapy in selected high-risk locally advanced HN cancers. Limited data has been reported on the timing of adjuvant HN radiation therapy when given concurrently with chemotherapy.
Study design: Retrospective case review of 16,733 patients with non-metastatic HN cancer (oral cavity, oropharynx, larynx, hypopharynx) who underwent curative intent surgery and received adjuvant chemoradiotherapy between 2004 and 2012.